|Podcasts|December 14, 2022

The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

In this episode, Christopher Bunick, MD, PhD, discusses a paper he recently co-authored, which explores JAK inhibitor safety compared to traditional systemic therapies for atopic dermatitis.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


Latest CME